Who can use Strensiq(asfotase alfa)?

The specific medical conditions the drug is approved to treat.

Approved Uses

STRENSIQ is indicated for the treatment of patients with perinatal/infantile-onset and juvenile-onset hypophosphatasia (HPP). This encompasses the severe forms of the disease that manifest at birth or in early infancy, as well as the form that presents later in childhood, addressing the core enzyme deficiency responsible for the debilitating skeletal and respiratory complications.

asfotase alfa(Strensiq)
Treatment of hypophosphatasia (HPP) in perinatal/infantile- and juvenile-onset patients.
RELATED ARTICLES
/ 0
0 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved